Pedro Ochoa-Allemant
@ochoaallemantmd.bsky.social
GI Fellow #Penn
Interested in preventing the development/progression of #SteatoticLiverDisease in high-risk patients
Peruano
Interested in preventing the development/progression of #SteatoticLiverDisease in high-risk patients
Peruano
Reposted by Pedro Ochoa-Allemant
👏 Congratulations to Pedro Ochoa-Allemant of the University of Pennsylvania for receiving the 2025 #AASLDFoundation Anna S. Lok Advanced/Transplant #Hepatology Fellow Award!
September 5, 2025 at 12:00 PM
👏 Congratulations to Pedro Ochoa-Allemant of the University of Pennsylvania for receiving the 2025 #AASLDFoundation Anna S. Lok Advanced/Transplant #Hepatology Fellow Award!
Reposted by Pedro Ochoa-Allemant
New research out in @jamainternalmed.com compares risk of adverse liver outcomes, cardiovascular events & mortality across steatotic liver disease subtypes ft. @ochoaallemantmd.bsky.social, David Kaplan, @SerperM (@PennGIHep) & @rhubbbstat.bsky.social (@BrownBiostats) jamanetwork.com/journals/jam...
June 25, 2025 at 7:36 PM
New research out in @jamainternalmed.com compares risk of adverse liver outcomes, cardiovascular events & mortality across steatotic liver disease subtypes ft. @ochoaallemantmd.bsky.social, David Kaplan, @SerperM (@PennGIHep) & @rhubbbstat.bsky.social (@BrownBiostats) jamanetwork.com/journals/jam...
🚨 Our last paper is out in @jamainternalmed.com
We compared the incidence of adverse liver outcomes, cardiovascular events, and mortality between MASLD, MetALD & ALD and found substantial differences!
🙏 @serperm.bsky.social @rhubbbstat.bsky.social & #DavidKaplan for their mentorship and support!
We compared the incidence of adverse liver outcomes, cardiovascular events, and mortality between MASLD, MetALD & ALD and found substantial differences!
🙏 @serperm.bsky.social @rhubbbstat.bsky.social & #DavidKaplan for their mentorship and support!
Patients with metabolic dysfunction and alcohol-associated liver disease and alcohol-associated liver disease have modestly higher risks of major adverse liver outcomes and all-cause mortality compared to those with MASLD.
https://ja.ma/4eoI8db
https://ja.ma/4eoI8db
June 18, 2025 at 2:45 PM
🚨 Our last paper is out in @jamainternalmed.com
We compared the incidence of adverse liver outcomes, cardiovascular events, and mortality between MASLD, MetALD & ALD and found substantial differences!
🙏 @serperm.bsky.social @rhubbbstat.bsky.social & #DavidKaplan for their mentorship and support!
We compared the incidence of adverse liver outcomes, cardiovascular events, and mortality between MASLD, MetALD & ALD and found substantial differences!
🙏 @serperm.bsky.social @rhubbbstat.bsky.social & #DavidKaplan for their mentorship and support!
🚨Check out our new study in @jhepatology.bsky.social ❗️
Using natural language processing to identify >350,000 patients with #steatosis, we demonstrated that cause-specific mortality differs between #MASLD #MetALD and #ALD
www.journal-of-hepatology.eu/article/S016...
Using natural language processing to identify >350,000 patients with #steatosis, we demonstrated that cause-specific mortality differs between #MASLD #MetALD and #ALD
www.journal-of-hepatology.eu/article/S016...
Cause-specific mortality in patients with steatotic liver disease in the United States
Causes of death across steatotic liver disease (SLD) subtypes remain incompletely
characterized in routine clinical practice. We aimed to quantify and compare cause-specific
mortality in SLD.
www.journal-of-hepatology.eu
May 29, 2025 at 10:53 PM
🚨Check out our new study in @jhepatology.bsky.social ❗️
Using natural language processing to identify >350,000 patients with #steatosis, we demonstrated that cause-specific mortality differs between #MASLD #MetALD and #ALD
www.journal-of-hepatology.eu/article/S016...
Using natural language processing to identify >350,000 patients with #steatosis, we demonstrated that cause-specific mortality differs between #MASLD #MetALD and #ALD
www.journal-of-hepatology.eu/article/S016...
Reposted by Pedro Ochoa-Allemant
This is an interesting letter to the editor that highlights the pitfalls of poorly validated ICD-10 codes and confirms my growing concerns with the increasingly popular but alarmingly weak TriNetX database and platform
@zachsmithgi.bsky.social
#gisky #liversky
@zachsmithgi.bsky.social
#gisky #liversky
March 9, 2025 at 1:47 AM
This is an interesting letter to the editor that highlights the pitfalls of poorly validated ICD-10 codes and confirms my growing concerns with the increasingly popular but alarmingly weak TriNetX database and platform
@zachsmithgi.bsky.social
#gisky #liversky
@zachsmithgi.bsky.social
#gisky #liversky